ATM and ovarian cancer: Whilst small molecule inhibitors of ATM and ATR are under clinical trial evaluation, Mre11 blockade could impair both ATM and ATR mediated pathways simultaneously and could be an effective strategy in ovarian cancers which frequently manifest genomic instability and replication stress.